These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2005-004135-22 Multicenter phase II study with docetaxel, 5-FU, leucovorin, and oxaliplatin in patients with metastatic or locally advanced gastric cancer or cancer of the esophagogastric junction- FLOT 2008-08-31 due-trials
Ongoing 2006-006936-24 A multicenter, randomised phase II trial on the therapy of advanced gastric cancer or adenocarcinoma of the esophagogastric junction in patients older than 65 years with special regard on quality of l... not-yet-due
Ongoing 2007-002828-15 An open-label, uncontrolled phase II trial of single agent sunitinib (SU 11248) for patients with chemo-refractory metastatic melanoma not-yet-due
Not reported 2008-002197-35 Multizentrische randomisierte Phase II Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC (Stadium IIIB/IV) mit Cisplatin/Docetaxel oder Oxaliplatin/Docetaxel 2011-11-23 due-trials
Ongoing 2009-018092-14 A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric carcinoma who have progressed after therapy with a fluoropyrimidine/plat... not-yet-due
Ongoing 2010-018754-13 A randomized multicenter Phase II/III Study comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) versus Epirubicin, Cisplatin and 5-FU (ECF) in patients with locally advanced resectable adeno... not-yet-due
Exempt Terminated 2011-003201-14 Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/n... not-yet-due
Completed, but no date 2014-002665-30 Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric juncti... bad-data